NYSE · LH
Labcorp Holdings Inc.
Healthcare · Medical - Diagnostics & Research
$313.64▼ 0.60% ($1.88)at close
As of 4:00 PM ET
Market cap
$25.72B
P/E
25.66
EPS (TTM)
$12.22
Next earnings
Oct 28, 2026
Valuation
Revenue & margin DCF
Verdict: fairly priced. Price above Base.
The price needs 5.0% revenue growth a year for 10 years. Our scenarios assume 2.2–4.4%.
That's 3.3× its past 4-year pace.
Value per share
Base case
$264.27
Price used $313.64 is 19% above this
USD · TTM ending Jun 30, 2026 · Price Oct 13, 8:00 PM UTC
Revenue each value needs
Revenue today $14.3B. The price needs $23.3B by 2036. Base case: $19.4B. At its recent pace: $16.7B. Bear to Bull: $17.8B to $22.1B.
Revenue today $14.3B. The price needs $23.3B by 2036. Base case: $19.4B. At its recent pace: $16.7B. Bear to Bull: $17.8B to $22.1B.
Revenue in 2036
today $14.3B
+$4Bmore than the Base case · 1.2×
Value per share · Base case
$264.27
Price $313.64
19% above this
- 10-yr revenue CAGR
- 3.0%
- Ending operating margin
- 11.3%
- Discount rate
- 7.7%
USD · TTM ending Jun 30, 2026 · Price Oct 13, 8:00 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock rose 13.37% over the last year. Revenue grew 6.41% over the trailing twelve months. Operating margin moved from 8.83% to 11.27%. Free cash flow declined 8.45% over the trailing twelve months.
What the market seems to be pricing
The stock is trading toward the richer end of its historical P/FCF range (92nd percentile) while business metrics are improving. More of the upside is already embedded in the multiple now.
What would invalidate this read
Operating margin is at 11.27% — continued expansion would be needed to justify the premium. Revenue growth of 6.41% is encouraging, but any deceleration puts the stretched multiple at risk. This read changes if revenue, margins, and cash flow continue to improve faster than expected — in that case the richer multiple could still prove conservative.
Return analysis
Company profile
Labcorp Holdings, Inc. offers vital diagnostic laboratory services, enabling medical professionals, healthcare facilities, pharmaceutical firms, scientific investigators, and patients to make well-informed and confident choices.
Market multiples
Stock splits
Every 250 shares became 291
Every 1 shares became 2
Every 1 shares became 2
Every 10 shares became 1
Profitability & growth
Analyst consensus
26
Buy
9
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Actuals vs estimates by quarter, or any quarter against the same one a year earlier.
Next report
Oct 28, 2026
Q3 FY26 · EPS est $4.65 · Revenue est $3.8B
Same quarter, year over year
FY26 YTD +12.8%Each cell vs the same quarter a year earlier (the cell below) · Q1–Q2 combined $9.24 vs $8.19 · all 2 quarters up
Q1
Q2
Q3
Q4
FY total
FY26
—
—
FY25
FY24
FY23
—
—
—
Fiscal year totals
- FY25
- $16.44
- +12.8%
- FY24
- $14.57
- —
Q2 FY26
Reported Jul 30, 2026 · Latest
HoverTap a cell to inspect
Actual
$4.99
Estimate
$4.78
Year over year
+14.7%
Vs prior quarter
+17.4%
Institutional Sentiment
Labcorp Holdings Inc. · LH
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.